Stage IIIA Skin Melanoma Recruiting Phase 1 Trials for Trametinib (DB08911)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02097225Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment